124 citations
,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
December 2023 in “International Journal of Dermatology”
9 citations
,
February 2022 in “Dermatology and therapy” An emollient PLUS balm with ADE-G1 significantly improved skin dryness and quality of life in cancer patients with xerosis.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
63 citations
,
July 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
November 2025 in “Journal of Investigative Dermatology” Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.
September 2023 in “Journal of the American Academy of Dermatology” ICI therapy increases the risk of gastrointestinal and endocrine issues in psoriasis patients.
79 citations
,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
1 citations
,
January 2014 in “Rinsho Shinkeigaku” Immunological treatment improved both neuropathy and alopecia.
November 2001 in “Oncology Times” The committee decided not to approve the drug due to low effectiveness and high risks.
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
3 citations
,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
11 citations
,
September 2010 in “PubMed” DHA-NLC may improve drug delivery and reduce side effects for cancer treatment.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.
June 2025 in “Veterinary Sciences” Oclacitinib effectively treated a diabetic cat's severe skin issues without raising glucose levels, and surgery fixed eyelid fusion.
38 citations
,
January 2016 in “Cell Death and Disease” The TCL1 transgenic mouse model is useful for understanding human B-cell leukemia and testing new treatments.
109 citations
,
March 2011 in “Journal of controlled release” New micelle solutions greatly improve skin delivery of certain antifungal drugs.
2 citations
,
December 2021 in “Journal of Veterinary Medical Science” Lokivetmab reduced itching in a dog with skin lymphoma.
11 citations
,
December 2010 in “Archives of Dermatology” A man with rare skin changes on his fingers was diagnosed with multiple myeloma-linked amyloidosis.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
January 2007 in “Frontiers in Medicine” Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.
September 2023 in “International Journal of Trichology” Tofacitinib helped a woman regrow hair with no major side effects.
April 2023 in “Journal of Investigative Dermatology” Contact immunotherapy can change immune responses in alopecia areata, suggesting new treatment targets.
July 2023 in “British journal of dermatology/British journal of dermatology, Supplement” Skin tumors with CYLD cutaneous syndrome show more NF-κB activity and less organized collagen.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
May 2018 in “Dermatologic Surgery” May 2022 in “Journal of Neurology Neurosurgery & Psychiatry” Erenumab significantly reduced migraine days or severity in most patients after 3 months.
1 citations
,
December 2022 in “The Nishinihon Journal of Dermatology” Baricitinib is an effective treatment for severe alopecia areata.